Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Near-term catalysts are limited to conference-driven sentiment and analyst price target momentum; the next hard catalyst (FDA update and 12-month data) is not expected until 1Q 2027, so short-term upside is likely modest and headline-dependent.
H.C. Wainwright lifted its Adicet Bio price target from $27 to $34 following updated prula-cel lupus data, reiterating a bullish stance. A sharply higher target versus the ~$3 share price can draw speculative attention and support near-term sentiment, though the wide gap also reflects high execution risk.
Yahoo Finance UKAt the Guggenheim Healthcare Innovation Conference, Adicet emphasized 50% complete renal response and 54% DORIS remission at 12 months, FDA alignment on the pivotal endpoint, and a plan to move directly to pivotal testing after stopping Phase 2 enrollment at 22 patients. Shares rose 1.67% to $3.04 on the day, indicating modest positive reception but lingering sector caution.
Investing.comAdicet reported Q3 2026 net loss of $18.9 million ($1.76/share) with $100.9 million in cash, sufficient to fund operations into 2H 2027. It disclosed pivotal LN study startup, a planned 4Q 2026 FDA meeting on expanding into non-renal lupus, and 1Q 2027 regulatory/data update, plus FDA IND clearance and Fast Track for ADI-212 in mCRPC. The runway removes immediate financing overhang but the next major catalyst is months away.
Adicet Bio Press ReleaseAdicet granted an inducement stock option for 1,500 shares at a $3.42 exercise price, a routine compensation action with negligible fundamental impact. It is included only for completeness and is unlikely to move the stock.
StockTitan